NHS England Offers Vertex Final Orkambi Deal
Executive Summary
The increasingly public row between Vertex and NHS England continues as NHS England claims it has offered Vertex the “largest ever financial commitment of its type” in its 70-year history. Meanwhile, Vertex has revealed that the NHS has offered a price that is significantly lower than the list price.
You may also be interested in...
‘Extreme Outlier’ Vertex Slammed For Orkambi Pricing Approach In England
Vertex has come under fire for its alleged extreme rigidity on pricing for its cystic fibrosis drug in England.
Vertex Rejects England’s Orkambi Offer
Vertex has rejected the “final offer” put forward by the National Health Service in England for its cystic fibrosis drugs, including Orkambi. The company’s chief executive wants a meeting with the head of the NHS.
Vertex Refuses To Back Down On England Orkambi Deal
Vertex is staunchly defending its cystic fibrosis portfolio-based reimbursement deal rejected by NHS England and has called on the UK’s prime minister to intervene. The company says similar deals have worked well in Ireland and Sweden.